Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma.

IF 5 Q1 ENGINEERING, BIOMEDICAL
BME frontiers Pub Date : 2025-06-24 eCollection Date: 2025-01-01 DOI:10.34133/bmef.0144
Roghayeh Naserkhaki, Bahare Shokouhian, Yaser Tahamtani, Arezoo Khosravi, Siavash Iravani, Ali Zarrabi, Massoud Vosough
{"title":"Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma.","authors":"Roghayeh Naserkhaki, Bahare Shokouhian, Yaser Tahamtani, Arezoo Khosravi, Siavash Iravani, Ali Zarrabi, Massoud Vosough","doi":"10.34133/bmef.0144","DOIUrl":null,"url":null,"abstract":"<p><p>One of the major therapeutic challenges for hepatocellular carcinoma (HCC), the most form of primary liver cancer, is how to overcome drug resistance. Due to the high failure rate of systemic therapy in treating advanced HCC patients and the increasing recurrence rate, HCC is a highly lethal malignancy. Primary and acquired drug resistance are major contributing factors to the patients with advanced HCC who do not respond effectively to long-term systemic therapy. Therefore, it is essential to look into the molecular processes that lead to drug resistance. Different studies have indicated that epithelial-to-mesenchymal transition (EMT) plays a critical part in the emergence of drug resistance. Several signaling pathways regulate this phenomenon. This review primarily concentrates on drug resistance triggered by EMT, especially in the context of HCC. The key signaling pathways that cause drug resistance in HCC, including transforming growth factor-β and epidermal growth factor receptor signaling, liver cancer stem cells, and noncoding RNAs, are highlighted in the present study, along with the most recent molecular targets discovered to prevent drug resistance. These targets could help develop novel and combinatory HCC therapy approaches. Therefore, this review aims to provide both the latest findings on molecular basis and potential solutions for HCC drug resistance.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0144"},"PeriodicalIF":5.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187357/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BME frontiers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34133/bmef.0144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

One of the major therapeutic challenges for hepatocellular carcinoma (HCC), the most form of primary liver cancer, is how to overcome drug resistance. Due to the high failure rate of systemic therapy in treating advanced HCC patients and the increasing recurrence rate, HCC is a highly lethal malignancy. Primary and acquired drug resistance are major contributing factors to the patients with advanced HCC who do not respond effectively to long-term systemic therapy. Therefore, it is essential to look into the molecular processes that lead to drug resistance. Different studies have indicated that epithelial-to-mesenchymal transition (EMT) plays a critical part in the emergence of drug resistance. Several signaling pathways regulate this phenomenon. This review primarily concentrates on drug resistance triggered by EMT, especially in the context of HCC. The key signaling pathways that cause drug resistance in HCC, including transforming growth factor-β and epidermal growth factor receptor signaling, liver cancer stem cells, and noncoding RNAs, are highlighted in the present study, along with the most recent molecular targets discovered to prevent drug resistance. These targets could help develop novel and combinatory HCC therapy approaches. Therefore, this review aims to provide both the latest findings on molecular basis and potential solutions for HCC drug resistance.

重新审视治疗策略:解决肝细胞癌上皮-间充质转化诱导的耐药。
肝细胞癌(HCC)是原发性肝癌的主要形式之一,如何克服耐药性是治疗肝癌的主要挑战之一。由于晚期HCC患者全身治疗失败率高,复发率不断增加,HCC是一种高致死率的恶性肿瘤。原发性和获得性耐药是晚期HCC患者对长期全身治疗无效的主要因素。因此,有必要研究导致耐药性的分子过程。不同的研究表明,上皮-间质转化(epithelial-to-mesenchymal transition, EMT)在耐药性的产生中起着关键作用。有几种信号通路调节这一现象。这篇综述主要集中在EMT引发的耐药,特别是在HCC的背景下。在本研究中强调了导致HCC耐药的关键信号通路,包括转化生长因子-β和表皮生长因子受体信号,肝癌干细胞和非编码rna,以及最近发现的预防耐药的分子靶点。这些靶点可能有助于开发新的HCC联合治疗方法。因此,本文旨在提供HCC耐药的分子基础和潜在的解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.10
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信